中国肺癌杂志Issue(10)：510-513,4.DOI:10.3779/j.issn.1009-3419.2013.10.02
吉非替尼治疗晚期非小细胞肺癌耐药后的进展模式分析
Progressive Patterns of Giiftinib Treating Advanced Non-small Cell Lung Cancer after Obtained Resistance
摘要
Abstract
Background and objective Clinical observation was conducted on the resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib (Iressa) therapy for advanced non-small cell lung cancer (NSCLC) patients. Methods Ninety-three NSCLC patients in our hospital, showing effective or stable condition after 6-month previous gefitinib therapy, were included in this investigation. Among the patients, 94.6%of them were suffering from adenocarcinoma. hTe percentage of female is 79.6%;the percentage of non-smoking is 80.6%. During the therapy period, follow-up was preformed every 2 months. Results Among the 93 patients, median therapy time was 16 months (range:8 to 70 months), and 21.5%(20/93) of them had received therapy for more than 2 years, while 8.6%(8/93) had received that for more than 3 years. hTe progression included 80%(72/90) for intrapleural progression, 38.9%(35/90) for primary tumor plus recurrence atfer sugary especially, 51.1%(46/90) for intrapulmonary metastasis, 25.6%(23/90) for pleural metastasis, 30%(30/90) for intracranial progression and 15.6%(14/90) for intraperitoneal progression. Conclusion Resistance to EGFR-TKI shows diversiifcation in clinical observation, therefore, close clinical follow-up is necessary for early attention and timely treatment.关键词
吉非替尼/肺肿瘤/耐药/转移Key words
Geiftinib/Lung neoplsams/Resistance/Metastasis引用本文复制引用
王彬,张昕,林琳,郝学志,张湘茹,李峻岭,石远凯..吉非替尼治疗晚期非小细胞肺癌耐药后的进展模式分析[J].中国肺癌杂志,2013,(10):510-513,4.基金项目
本研究受国家“重大新药创制”科技重大专项“十一?五”课题（No.2008ZX09312-020）；国家“重大新药创制”科技重大专项“十二?五”课题（No.2012ZX09303-012）；北京市科技计划项目（No. Z111102071011001）；中央保健课题（No.B2009B124）资助 （）
